CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

Al-Azawi, Dhafir; Kelly, Gabrielle; Myers, E.; McDermott, Enda; Hill, A. D. K.; Duffy, Michael J.; Higgins, N

doi:10.1186/1471-2407-6-220

Cited by 64 publications

(44 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, outcome was favorable in patients with negative hormonal receptor status or HER2 overexpression following chemotherapy for breast cancer, consistent with previous studies [25,26,28]. However, other studies have found no association with treatment response [27,29]. These discordant results may be due to the small number of patients, the heterogeneous patient populations and chemotherapy regimens analyzed as well as differing selection criteria.…”

Section: Discussioncontrasting

confidence: 31%

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

Mao

Guan²,

Tucker³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

Objective: This phase II study was designed to evaluate the effects of vinorelbine (VRL) and capecitabine (CAP) as second-line combination chemotherapy in patients with advanced breast cancer (ABC) previously treated with anthracyclines and/or taxanes. Methods: Treatment consisted of VRL 25 mg/m² administered on days 1 and 8 of a 21-day treatment cycle, along with oral CAP 825 mg/m² twice daily for 14 days, followed by 7 days of rest. Results: 50 patients were enrolled and 48/50 (96.0%) patients were assessable for response. The median time to progression (TTP) and overall survival (OS) of the patients were 5.0 (95% confidence interval, CI, 2.1–7.9 months) and 12.0 months (95% CI, 8.0–16.0 months), respectively. The objective response rate was 26.0% (95% CI, 13.8–38.2%) with 1 confirmed complete response and 12 partial responses. The most frequent hematological adverse event was neutropenia of grade 3 and 4 in 5 (10.4%) and 2 patients (4.2%), respectively. Grade 3 stomatitis, asthenia, and diarrhea were observed in 1 (2.1%), 2 (4.2%) and 3 (6.3%) patients, respectively. Conclusion: The combination of VRL and CAP is feasible as second-line chemotherapy in patients with ABC previously treated with anthracyclines and/or taxanes, with efficacy being comparable to other available combination regimens.

show abstract

Section: Discussioncontrasting

confidence: 31%

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

Mao

Guan²,

Tucker³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…In breast cancer the role of serum markers is less well established [1][2][3]. The elevation of serum markers in breast cancer may be helpful in early diagnosis, determining prognosis, predicting response or resistance to specific therapies, surveillance after primary surgery, and monitoring therapy in patients with advanced disease [4][5][6]. Breast cancer is a heterogenic disease and none of the available markers is increased in all patients with breast cancer even in an advanced stage of the disease [2,4].…”

Section: Introductionmentioning

confidence: 99%

The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type.

Agrawal

Jeleń²,

Rudnicki³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Material and methodsTumour samples. A total of 428 patients were treated at The Department of Surgery of Wroclaw Medical University from 2005 to 2008 due to the diagnosis of breast cancer. All of them had their preoperative CA 15-3 and CEA serum concentrations measured. In all patients tumours were invasive cancers in stages I-III, and the mean age of patients was 52.5 years (range 24-83 years). All the patients in the study were women and 54.5% of them were postmenopausal.Tumour markers. Studied tumour markers levels were measured by immunoassays: Enzymum test 300 using the cutoff value of 5 ng/ml for CEA and Enzymum-test CA 15-3 using the cutoff value of 40 units/ml for CA 15.3. Intra-and interassay variations for both markers were 5% and 10%, respectively. Measurements of serum concentrations of CEA and CA 15-3 were blinded. In all cases histological slides from paraffin wax embedded material Abstract: It is not known whether in patients with breast cancer the occurrence of elevated serum tumour markers depends on its histological type. The aim of the study was to assess relationship between breast cancer histological type and the presence of increased serum levels of CEA and CA 15-3. The study population was 428 patients (all women, mean age 52.5 years), treated at The Department of Surgery of Wroclaw Medical University from 2005 to 2008 due to breast cancer. All of them had their preoperative CA 15-3 and CEA serum concentrations measured. According to the TNM system, 21% of patients were in stage I, 32.5% in stage II, 46.5% in stage III of the disease. In patients with ductal type of the cancer the elevated serum levels of CEA and CA 15-3 were observed in 48.7% and 42.2%, in lobular type in 42.4% and 52.5%, and in non-ductal/tubular types in 48.1% and 40.4% (p=N/S). Stepwise logistic regression analyses showed that ductal breast cancer is related to elevated CEA and normal CA 15-3 serum levels. The histological types of breast cancer are not significantly related to elevated serum levels of CEA and/or CA 15-3.

show abstract

“…Understandably, because of its abundant expression and remarkable relevance to the development of the pathology, MUc-1 is the most widely used serum marker for breast cancer (1).…”

Section: Imaging Target-umuc-1 Tumor Antigenmentioning

confidence: 99%

“…As a molecule directly involved in cell adhesion and proliferation, it is not surprising that MUc-1 expression is highly correlated with both tumor growth and metastatic potential, making it an important predictive marker not only for the transition from early to locally advanced disease but also for the progression to advanced malignancy (57,66,75,89). in addition to being an excellent marker for the prediction and characterization of tumor progression, MUc-1 availability is also directly related to treatment outcome, making this target antigen one of the most widely used markers of therapeutic response and disease recurrence, particularly in patients with locally advanced and invasive disease (1). in patients treated with neoadjuvant chemotherapy, MUC-1 levels were found to be consistently reduced, suggesting that MUc1 can be explored as an intermediate biomarker for assessment of treatment and prognosis (27).…”

Section: Imaging Target-umuc-1 Tumor Antigenmentioning

confidence: 99%

Noninvasive Imaging of Breast Cancer

Medarova

2009

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

Abstract: Background: Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer.

Cited by 64 publications

References 18 publications

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type.

Noninvasive Imaging of Breast Cancer

Contact Info

Product

Resources

About